(AOF) – Laboratoires Boiron announces a net income group share up 23.5% to 15.46 million euros in the first half of 2023, for a turnover down 6.6% to 239, 88 million euros. The laboratory adds that its operating profit is down 11.1% over the period to 17.78 million for net cash of 231.18 million, down 4.8% over one year. The group attributes the 6.6% decrease in sales over the half-year in the first place “to the base effect coming from the significant sales of Covid tests in the first half of 2022”.
He also points to “the decline in France in sales of common-name homeopathic medicines”.
The gross margin increased from 67.1% to 72.9% of turnover following the drop in the share of Covid tests in the activity of the semester. Operating expenses increased by 7.25 million euros, taking into account in particular promotional expenses which rose by 5.24 million, particularly in France, Italy and the United States.
Boiron estimates that the evolution of the Group’s sales in 2023 will depend “on the continuation of the current momentum in homeopathic specialties”, as well as “upcoming launches” and the “level of pathology at the end of the year”. . According to management, sales for the year 2023 “could show a slight decline compared to 2022”. However, given the evolution of the product mix and the exceptional adjustments already recorded, operating profit “could be up compared to 2022”.
AOF – LEARN MORE
Find out more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in financing by venture capital for start-ups. These companies are therefore obliged to carry out redundancy plans. Added to this is a much more restrictive regulatory framework. First, in the United States, the measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of the participants. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemicals) or 13 years (biologicals), with discounts that could range from 35 to 60% for biotechs. Similarly, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.